TY - JOUR
T1 - Nanotechnologies for Alzheimer's disease
T2 - Diagnosis, therapy, and safety issues
AU - Brambilla, Davide
AU - Le Droumaguet, Benjamin
AU - Nicolas, Julien
AU - Hashemi, S. Hossein
AU - Wu, Lin Ping
AU - Moghimi, S. Moein
AU - Couvreur, Patrick
AU - Andrieux, Karine
N1 - Funding Information:
This study was supported by the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 212043 ; the French Ministry of Research and CNRS ; (to S.M.M.) Danish Agency for Science, Technology and Innovation (Det Strategiske Forskningsråd, reference 09-065746/DSF ) and Lundbeck S/A .
PY - 2011/10
Y1 - 2011/10
N2 - Alzheimer's disease (AD) represents the most common form of dementia worldwide, affecting more than 35 million people. Advances in nanotechnology are beginning to exert a significant impact in neurology. These approaches, which are often based on the design and engineering of a plethora of nanoparticulate entities with high specificity for brain capillary endothelial cells, are currently being applied to early AD diagnosis and treatment. In addition, nanoparticles (NPs) with high affinity for the circulating amyloid-β (Aβ) forms may induce "sink effect" and improve the AD condition. There are also developments in relation to in vitro diagnostics for AD, including ultrasensitive NP-based bio-barcodes, immunosensors, as well as scanning tunneling microscopy procedures capable of detecting Aβ 1-40 and Aβ 1-42. However, there are concerns regarding the initiation of possible NP-mediated adverse events in AD, thus demanding the use of precisely assembled nanoconstructs from biocompatible materials. Key advances and safety issues are reviewed and discussed. From the Clinical Editor: This excellent review summarizes the impact of nanotechnology on the diagnosis and treatment of Alzheimer's disease, ranging from circulating amyloid 'sinks' to NP-based bio-barcodes and many other recent advances, without neglecting potential pitfalls, side effects and safety issues. A must read for anyone interested in the evolving interface of clinical neurosciences and nanotechnology.
AB - Alzheimer's disease (AD) represents the most common form of dementia worldwide, affecting more than 35 million people. Advances in nanotechnology are beginning to exert a significant impact in neurology. These approaches, which are often based on the design and engineering of a plethora of nanoparticulate entities with high specificity for brain capillary endothelial cells, are currently being applied to early AD diagnosis and treatment. In addition, nanoparticles (NPs) with high affinity for the circulating amyloid-β (Aβ) forms may induce "sink effect" and improve the AD condition. There are also developments in relation to in vitro diagnostics for AD, including ultrasensitive NP-based bio-barcodes, immunosensors, as well as scanning tunneling microscopy procedures capable of detecting Aβ 1-40 and Aβ 1-42. However, there are concerns regarding the initiation of possible NP-mediated adverse events in AD, thus demanding the use of precisely assembled nanoconstructs from biocompatible materials. Key advances and safety issues are reviewed and discussed. From the Clinical Editor: This excellent review summarizes the impact of nanotechnology on the diagnosis and treatment of Alzheimer's disease, ranging from circulating amyloid 'sinks' to NP-based bio-barcodes and many other recent advances, without neglecting potential pitfalls, side effects and safety issues. A must read for anyone interested in the evolving interface of clinical neurosciences and nanotechnology.
KW - Aβ peptide
KW - Alzheimer's disease
KW - Drug delivery
KW - Nanoparticles
KW - Nanotechnology
UR - http://www.scopus.com/inward/record.url?scp=80053212172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053212172&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2011.03.008
DO - 10.1016/j.nano.2011.03.008
M3 - Review article
C2 - 21477665
AN - SCOPUS:80053212172
SN - 1549-9634
VL - 7
SP - 521
EP - 540
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 5
ER -